RegeneRx drug candidate, RGN-259, is the subject of four Phase 3 clinical trials in the U.S. for patients with dry eye disease (DED) and neurotrophic keratitis (NK, an orphan indication). The results of these trials were announced in 2021 and 2020 and demonstrated a number of statistically significant imporvements in both signs and symptoms of DED, as well as NK compared to placebo.